Pieris: Main Line biotech firm completes reverse merger, raises $78.9 million
The focus of the combined company is developing new treatment for rare genetic skin diseases.
Read full article »
Pieris is a Massachusetts-based biotechnology company that develops and commercializes anticalin-derived drugs for the treatment of cancer and respiratory diseases.
Read more